Clinical trial solutions provider WCG has launched the new software-as-a-service (SaaS) technology, ClinSphere Total Feasibility, to enhance site selection.
It is aimed at improving the decision-making processes for sponsors and contract research organisations (CROs) for clinical trial start-ups.
Go deeper with GlobalData
This solution provides centralised access to trial data, helping to decrease redundancy and improve the feasibility and selection activities of the site.
It uses WCG’s extensive data and features ‘pre-populated’ surveys to minimise the workload at the site and expedite responses.
In addition, the solution claims to double the site feasibility response rate against the industry average. It also helps to reduce the timeline and burden for sites and sponsors during the site assessment and selection process.
Users will be able to access comprehensive details on site offerings, staff, and logistics through over 300 standardised fields.
The software features a self-service or high-touch experience option, with wrap-around services, offering clinical development insights and site detection for end-to-end trial start-up support.
WCG noted that the solution features real-time tracking, scoring, and analysis of responses, allowing for quick decision-making.
It claims to decrease redundancy, enhance partnerships, accelerate outcomes, decrease the site workload, and offer rapid turnaround times.
The self-service ability of the solution provides CROs and sponsors with a tool to ‘streamline’ operations, minimise expenses, and enhance site relationships during the trial feasibility process.
WCG CEO Sam Srivastava said: “WCG ClinSphere Total Feasibility revolutionises the study start-up process.
“By integrating comprehensive data combined with user-friendly tools, we empower research teams with the insights they need to make informed decisions quickly. This innovation is central to our mission to improve lives by accelerating research, bringing life-saving treatments to patients sooner.”
In May 2023, WCG introduced an integrated solution to meet the ICH E8 R1 needs and improve trial predictability.
